- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients | ||
| Fr | MrBeast, Snapchat, AI and more: Pharma marketing's pulse check | ||
| Fr | Biogen enlists lupus patient advocate to share social media story of resilience | ||
| Fr | Stephen Farquhar takes over as CEO of Publicis Health Media | ||
| Fr | Omnicom PR consultancy injects new leadership into pharma push | ||
| Do | BMS splashes out $173M to build 2nd radiopharmaceutical plant in Indiana | ||
| Do | As RevMed preps for 'historic' pancreatic cancer launch, questions linger on the ground | ||
| Do | PhRMA's Medicare price negotiation suit rebuffed in latest blow to industry IRA challenge | ||
| Do | Amgen, AstraZeneca's Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent | ||
| Do | Artis BioSolutions expands synthetic DNA, mRNA production with Spanish facility | ||
| Do | Trump set to reveal MFN pricing deals with mid-sized companies: report | ||
| Mi | FDA greenlights Revolution Medicines' pancreatic cancer gamechanger | ||
| Mi | Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate | ||
| Mi | Baxter issues recall of 2 products after particulate concerns resurface | ||
| Mi | With Trump's nominee pick in, FDA weighs new deputy commissioner posts: report | ||
| Di | NAD reaches split decision on hair ad row between Kenvue and Hims & Hers | ||
| Di | McKesson strikes $2.25B deal to snap up Precision Medicine Group | ||
| Di | Bausch + Lomb flops in ph. 2 with Xiidra and Miebo but advances combo to ph. 3 | ||
| Di | Johnson & Johnson scores 1st FDA label expansion for Imaavy | ||
| Mo | Merck, AstraZeneca lawsuits against Medicare price negotiations swatted down | ||
| Mo | Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdict | ||
| Mo | After Trump order, RFK Jr. seeks input on US pediatric vaccine recommendations | ||
| Mo | Cellares CEO seeks to 'resize' company after loss of 'large' cell therapy manufacturing customer | ||
| Mo | Daiichi Sankyo promotes Ken Keller to lead new commercialization unit | ||
| 21.08. | Lundbeck continues neuroscience evolution as CEO keeps company 'punching above its weight' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.